VentriPoint Diagnostics (CVE:VPT) Stock Price Down 14.7% – Should You Sell?
by Danessa Lincoln · The Markets DailyShares of VentriPoint Diagnostics Ltd. (CVE:VPT – Get Free Report) fell 14.7% on Tuesday . The company traded as low as C$0.15 and last traded at C$0.15. 266,015 shares changed hands during mid-day trading, a decline of 10% from the average session volume of 294,436 shares. The stock had previously closed at C$0.17.
VentriPoint Diagnostics Stock Down 14.7 %
The company has a current ratio of 0.28, a quick ratio of 6.67 and a debt-to-equity ratio of -58.56. The firm has a 50 day moving average price of C$0.10 and a 200-day moving average price of C$0.13. The firm has a market cap of C$23.52 million, a price-to-earnings ratio of -4.48 and a beta of 0.39.
About VentriPoint Diagnostics
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers.
Recommended Stories
- Five stocks we like better than VentriPoint Diagnostics
- How to Profit From Growth Investing
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- When to Sell a Stock for Profit or Loss
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Stock Dividend Cuts Happen Are You Ready?
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave